Market Cap 3.06B
Revenue (ttm) 300,000.00
Net Income (ttm) -269.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,983.33%
Debt to Equity Ratio 0.04
Volume 673,700
Avg Vol 1,544,836
Day's Range N/A - N/A
Shares Out 95.44M
Stochastic %K 58%
Beta 0.87
Analysts Strong Sell
Price Target $41.29

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 401, Waltham, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:45 AM
Actionable Trade Alert: $VRDN Market Context: $VRDN is currently trading at $32.46, showing strong momentum as indicated by an RSI of 71.84, suggesting overbought conditions. However, the price is near its 60D High of $33.34, indicating potential resistance. Directional Bias: The bullish sentiment is supported by the MA30 at $27.55 and MA50 at $25.21, both below the current price, signaling upward momentum. The high-low range indicates a strong potential for profit, with room to target higher levels before potential pullbacks. Trade Plan: - Suggested Entry: $32.50 - Stop Loss: $30.00 (1.26 ATR below entry) - Take Profit Targets: 1. $34.00 (4.6% ROI) 2. $36.00 (10.2% ROI) 3. $38.00 (17.9% ROI) With a clear strategy and defined targets, this trade offers a favorable risk-reward ratio. Monitor closely for any signs of reversal given the RSI levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:20 PM
Actionable Trade Alert: $VRDN Market Context: $VRDN is currently trading at $32.46, showing strong momentum as indicated by an RSI of 71.84, suggesting overbought conditions. However, the price is near its 60D High of $33.34, indicating potential resistance. Directional Bias: The bullish sentiment is supported by the MA30 at $27.55 and MA50 at $25.21, both below the current price, signaling upward momentum. The high-low range indicates a strong potential for profit, with room to target higher levels before potential pullbacks. Trade Plan: - Suggested Entry: $32.50 - Stop Loss: $30.00 (1.26 ATR below entry) - Take Profit Targets: 1. $34.00 (4.6% ROI) 2. $36.00 (10.2% ROI) 3. $38.00 (17.9% ROI) With a clear strategy and defined targets, this trade offers a favorable risk-reward ratio. Monitor closely for any signs of reversal given the RSI levels. https://privateprofiteers.com
0 · Reply
Butch44
Butch44 Dec. 4 at 6:59 PM
$VRDN 🔥🔥🔥🔥
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 4 at 1:23 PM
$VRDN William Blair sees modest market expansion... try 3x. Tepezza is NOT effective in chronic TED; Veligrotug will dominate TED in chronic which represents 75% of the total TAM.... Amgen can not sell Tepezza into chronic even with the FDA label expansion. Lets up that acquistion target to $55-60. 2026 M&A target
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 3 at 9:46 PM
$VRDN You want a value driver, William Blair?? What's the only treatment clinically proven to show a therapeutic advantage in chronic TED? Veligrotug...not Tepezza. Chronic is 75% of the total TAM and Tepezza's ineffectiveness in chronic setting is why it's sales growth plateaued even though FDA expanded the original label to include chronic. Better than Tepezza....
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 3 at 9:41 PM
$VRDN File this under "No sh*& Sherlock": William Blair initiated coverage on Viridian Therapeutics Inc. ( VRDN ) on Wednesday. Analyst Lachlan Hanbury-Brown writes that the company's anti-IGF-1R franchise represents a meaningful advance compared to Amgen Inc.’s Tepezza (teprotumumab-trbw) for thyroid eye disease (TED). William Blair writes that Tepezza generates annual U.S. sales of roughly $2 billion with only single-digit penetration of the moderate-to-severe TED market, making for a favorable commercial environment for veligrotug, as it has some advantages over Tepezza. Veligrotug requires fewer infusions (5 versus 8), and each infusion is shorter (30-45 minutes versus 60-90 minutes), a lower overall dose may offer an improved safety profile, and it appears to have a more rapid onset of efficacy. William Blair initiated with an Outperform rating and a fair value estimate of $47.
1 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 2:30 PM
William Blair has updated their rating for Viridian Therapeutics ( $VRDN ) to Outperform.
0 · Reply
Quantumup
Quantumup Dec. 3 at 11:46 AM
William Blair🏁 $VRDN at an Outperform rating. $AMGN $NVS $ALPMY $RHHBY William Blair said, we are initiating coverage of Viridian with an Outperform rating and $47 fair value estimate, based on our belief that the company's anti-IGF-1R franchise represents a meaningful advance compared to Tepezza for the treatment of thyroid eye disease (TED). While we acknowledge that growth in the U.S. TED market has plateaued in recent years, we believe that new therapies offering a more convenient administration, cleaner picture of the adverse event profile of IGF-1R inhibition, and diplopia benefit in chronic disease have potential to grow the market. In particular, while we believe veligrotug has important advantages over Tepezza that could drive share capture and modest market expansion following a potential mid-2026 approval, we believe the bigger value driver is the subcutaneously administered VRDN-003, for which top-line Phase III data are expected in the first and second quarters of 2026.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:51 AM
0 · Reply
Butch44
Butch44 Nov. 28 at 3:34 PM
$VRDN take a look at TRVI. Great phase 2 data for chronic cough. Heavily owned by institutions
0 · Reply
Latest News on VRDN
Viridian Therapeutics Is Ready For An Eventful 2026

Nov 6, 2025, 9:20 AM EST - 4 weeks ago

Viridian Therapeutics Is Ready For An Eventful 2026


Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease

Sep 26, 2025, 10:56 AM EDT - 2 months ago

Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease


Viridian (VRDN) Q2 Net Loss Widens 55%

Aug 6, 2025, 12:28 PM EDT - 4 months ago

Viridian (VRDN) Q2 Net Loss Widens 55%


Viridian Therapeutics: The Song Remains The Same

Jun 9, 2025, 6:18 PM EDT - 6 months ago

Viridian Therapeutics: The Song Remains The Same


Viridian Therapeutics' Superior Prospects Make It A Buy

Oct 23, 2024, 4:02 PM EDT - 1 year ago

Viridian Therapeutics' Superior Prospects Make It A Buy


3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

AUPH CORT


Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRNA


3 Biotech Names With Potential Catalysts By Year End

Jul 29, 2024, 3:32 PM EDT - 1 year ago

3 Biotech Names With Potential Catalysts By Year End

CADL RCKT


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:45 AM
Actionable Trade Alert: $VRDN Market Context: $VRDN is currently trading at $32.46, showing strong momentum as indicated by an RSI of 71.84, suggesting overbought conditions. However, the price is near its 60D High of $33.34, indicating potential resistance. Directional Bias: The bullish sentiment is supported by the MA30 at $27.55 and MA50 at $25.21, both below the current price, signaling upward momentum. The high-low range indicates a strong potential for profit, with room to target higher levels before potential pullbacks. Trade Plan: - Suggested Entry: $32.50 - Stop Loss: $30.00 (1.26 ATR below entry) - Take Profit Targets: 1. $34.00 (4.6% ROI) 2. $36.00 (10.2% ROI) 3. $38.00 (17.9% ROI) With a clear strategy and defined targets, this trade offers a favorable risk-reward ratio. Monitor closely for any signs of reversal given the RSI levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:20 PM
Actionable Trade Alert: $VRDN Market Context: $VRDN is currently trading at $32.46, showing strong momentum as indicated by an RSI of 71.84, suggesting overbought conditions. However, the price is near its 60D High of $33.34, indicating potential resistance. Directional Bias: The bullish sentiment is supported by the MA30 at $27.55 and MA50 at $25.21, both below the current price, signaling upward momentum. The high-low range indicates a strong potential for profit, with room to target higher levels before potential pullbacks. Trade Plan: - Suggested Entry: $32.50 - Stop Loss: $30.00 (1.26 ATR below entry) - Take Profit Targets: 1. $34.00 (4.6% ROI) 2. $36.00 (10.2% ROI) 3. $38.00 (17.9% ROI) With a clear strategy and defined targets, this trade offers a favorable risk-reward ratio. Monitor closely for any signs of reversal given the RSI levels. https://privateprofiteers.com
0 · Reply
Butch44
Butch44 Dec. 4 at 6:59 PM
$VRDN 🔥🔥🔥🔥
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 4 at 1:23 PM
$VRDN William Blair sees modest market expansion... try 3x. Tepezza is NOT effective in chronic TED; Veligrotug will dominate TED in chronic which represents 75% of the total TAM.... Amgen can not sell Tepezza into chronic even with the FDA label expansion. Lets up that acquistion target to $55-60. 2026 M&A target
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 3 at 9:46 PM
$VRDN You want a value driver, William Blair?? What's the only treatment clinically proven to show a therapeutic advantage in chronic TED? Veligrotug...not Tepezza. Chronic is 75% of the total TAM and Tepezza's ineffectiveness in chronic setting is why it's sales growth plateaued even though FDA expanded the original label to include chronic. Better than Tepezza....
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 3 at 9:41 PM
$VRDN File this under "No sh*& Sherlock": William Blair initiated coverage on Viridian Therapeutics Inc. ( VRDN ) on Wednesday. Analyst Lachlan Hanbury-Brown writes that the company's anti-IGF-1R franchise represents a meaningful advance compared to Amgen Inc.’s Tepezza (teprotumumab-trbw) for thyroid eye disease (TED). William Blair writes that Tepezza generates annual U.S. sales of roughly $2 billion with only single-digit penetration of the moderate-to-severe TED market, making for a favorable commercial environment for veligrotug, as it has some advantages over Tepezza. Veligrotug requires fewer infusions (5 versus 8), and each infusion is shorter (30-45 minutes versus 60-90 minutes), a lower overall dose may offer an improved safety profile, and it appears to have a more rapid onset of efficacy. William Blair initiated with an Outperform rating and a fair value estimate of $47.
1 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 2:30 PM
William Blair has updated their rating for Viridian Therapeutics ( $VRDN ) to Outperform.
0 · Reply
Quantumup
Quantumup Dec. 3 at 11:46 AM
William Blair🏁 $VRDN at an Outperform rating. $AMGN $NVS $ALPMY $RHHBY William Blair said, we are initiating coverage of Viridian with an Outperform rating and $47 fair value estimate, based on our belief that the company's anti-IGF-1R franchise represents a meaningful advance compared to Tepezza for the treatment of thyroid eye disease (TED). While we acknowledge that growth in the U.S. TED market has plateaued in recent years, we believe that new therapies offering a more convenient administration, cleaner picture of the adverse event profile of IGF-1R inhibition, and diplopia benefit in chronic disease have potential to grow the market. In particular, while we believe veligrotug has important advantages over Tepezza that could drive share capture and modest market expansion following a potential mid-2026 approval, we believe the bigger value driver is the subcutaneously administered VRDN-003, for which top-line Phase III data are expected in the first and second quarters of 2026.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:51 AM
0 · Reply
Butch44
Butch44 Nov. 28 at 3:34 PM
$VRDN take a look at TRVI. Great phase 2 data for chronic cough. Heavily owned by institutions
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 28 at 2:45 PM
$VRDN $SNDX $SRRK $NVCR $CADL Thankful for the bio resurgence, expecting 2026 to be a very active M&A environment. Bio is cyclical and we are in early stages of would could be massive feeding frenzy. GLTA
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 25 at 12:41 AM
$VRDN Shorts starting to sizzzzzzle.
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 6:03 PM
Truist Securities has adjusted their stance on Viridian Therapeutics ( $VRDN ), setting the rating to Buy with a target price of 41.
0 · Reply
Quantumup
Quantumup Nov. 24 at 3:20 PM
Truist🏁 $VRDN Buy-$41 and said—We think VRDN is well-positioned following veligrotug's (Veli') BLA submission and potential launch in thyroid eye disease (TED). $AMGN $NVS $ALPMY $RHHBY Truist additionally said in its initiation report—Our valuation is driven by Veli', a full IGF-1R antagonist, which has shown differentiated efficacy — with markedly reduced treatment burden — in active and chronic TED, with support from KOLs, justifying our est. of a WW peak sales opportunity of ~$730M by 2031. We also see the layering of a larger opportunity for VRDN-003, a half-life extended subcutaneous (SC) formulation, which we est. could command a WW peak sales opportunity of $1.5B in 2034. An early autoimmune pipeline diversifies the opportunity.
0 · Reply
buylocellhi
buylocellhi Nov. 24 at 2:51 PM
$VRDN squeeze to $40
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 24 at 2:37 PM
$VRDN $SNDX $SRRK Most likely M&A targets in 2026
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 24 at 1:57 PM
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 23 at 3:06 PM
$NVCR $VRDN $TMDX $SNDX A worthy cause to consider: We are just 20 days away from National Wreaths Across America Day! Will you join us on Saturday, December 13, as millions across the country come together to Remember, Honor, Teach at over 5,600 participating locations? Your support over the years has made an incredible impact, but now is the time to join the mission in 2025! By sponsoring a veteran’s wreath, you can play a vital role in our mission to remember every U.S. servicemember, while honoring the veterans in your community. https://wreathsacrossamerica.org/Shop/Product/597?tid=8E82D485-0232-465D-B42B-C6A73D889BB7
0 · Reply
JFais
JFais Nov. 22 at 2:47 PM
$VRDN- nearly tripled from lows. Agree with Houbi (in past revisits felt like a "me too" drug developer, though playing in admittedly large markets)
2 · Reply
Tdorsey1776
Tdorsey1776 Nov. 21 at 3:06 PM
$VRDN Going higher, likely M&A target in 2026
0 · Reply
Nosh
Nosh Nov. 21 at 2:28 AM
$VRDN 👀👀
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 18 at 5:21 PM
0 · Reply